Redcliffe Labs operates an omnichannel diagnostics platform offering lab testing, an extensive collection network and home‑collection services. The company serves over 7 million patients across more than 220 cities via 80 labs and 2,000+ collection centers. It plans to expand into Tier II and III Indian cities, open new labs, enhance its collection network and scale home‑collection offerings. Growth has been supported by strategic acquisitions in North‑Western India and partnerships with diagnostic chains. Leadership hires include Ankur Shah as an independent director and Alka Saxena as CFO, and the company highlights NABL accreditation and Six Sigma practices. Financially, operating revenue grew 2.6x to ₹347 crore in FY23 while losses widened fivefold to ₹345.6 crore, reflecting rapid expansion investments. Redcliffe Lifetech is a Noida, India–based diagnostics company that delivers pathology and specialised testing through an omni-channel infrastructure. Its network comprises 22 labs across 14 cities, several of which are NABL accredited, supported by a fleet of 400 phlebotomists operating in 100+ cities and an offline network of 500 collection centres. The company offers more than 3,500 different pathology and specialised tests, including genetics, at affordable prices. Redcliffe plans to expand its geographic reach across India with a focus on tier 2, 3 and 4 cities, scale its platform, and increase product offerings to radiology, disease data profiling and lifestyle management. Led by founder Dheeraj Jain, the business combines online channels, home sample collection, and an extensive offline footprint to reach consumers. The company will use the new funding to execute these expansion and product plans.

Total raised

$103M

Funding rounds

2

Latest round

Series C

Latest activity

Sep 2024